4.7 Article

2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists

Journal

BIOORGANIC & MEDICINAL CHEMISTRY
Volume 24, Issue 11, Pages 2530-2543

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2016.04.019

Keywords

Formyl peptide receptor (FPR); Agonist; Pyridazin-3(2H)-one; Neutrophil; Ca2+ mobilization

Funding

  1. EPSRC [EP/I017887/1]
  2. National Institutes of Health IDeA Program COBRE grant [GM110732, AI033503]
  3. M.J. Murdock Charitable Trust
  4. USDA National Institute of Food and Agriculture Hatch project
  5. Montana University System Research Initiative [51040-MUSRI2015-03]
  6. Montana State University Agricultural Experiment Station
  7. Engineering and Physical Sciences Research Council [EP/I017887/1] Funding Source: researchfish
  8. EPSRC [EP/I017887/1] Funding Source: UKRI

Ask authors/readers for more resources

N-Formyl peptide receptors (FPRs: FPR1, FPR2, and FPR3) are G protein-coupled receptors that play key roles in modulating immune cells. FPRs represent potentially important therapeutic targets for the development of drugs that could enhance endogenous anti-inflammation systems associated with various pathologies, thereby reducing the progression of inflammatory conditions. Previously, we identified 2-arylacetamide pyridazin-3(2H)-ones as FPR1- or FPR2-selective agonists, as well as a large number of FPR1/FPR2-dual agonists and several mixed-agonists for the three FPR isoforms. Here, we report a new series of 2-arylacetamido-4-aniline pyridazin-3(2H)-ones substituted in position 5 as a further development of these FPR agonists. Chemical manipulation presented in this work resulted in mixed FPR agonists 8a, 13a and 27b, which had EC50 values in nanomolar range. In particular, compound 8a showed a preference for FPR1 (EC50 = 45 nM), while 13a and 27b showed a moderate preference for FPR2 (EC50 = 35 and 61 nM, respectively). Thus, these compounds may represent valuable tools for studying FPR activation and signaling. (C) 2016 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available